Alpha 2.0
Login Register
» Authors » Anais Domergue

Anais Domergue

Explore the profile of Anais Domergue including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 525
Followers 0
Related Specialties
General Medicine
Pharmacology
Infectious Diseases
Top 10 Co-Authors
Valentine Duru
Saorin Kim
Nimol Khim
Benoit Witkowski
Rithea Leang
Didier Menard
Nimol Kloeung
Didier Laureillard
Odile Mercereau-Puijalon
Pascal Ringwald
Published In
Lancet Infect Dis
Antimicrob Agents Chemother
Skin Pharmacol Physiol
BMC Med
N Engl J Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial
de Castro N, Marcy O, Chazallon C, Messou E, Eholie S, Ntakpe J, et al.
Lancet Infect Dis . 2021 Mar; 21(6):813-822. PMID: 33667406
Background: In patients co-infected with HIV and tuberculosis, antiretroviral therapy options are limited due to drug-drug interactions with rifampicin. A previous phase 2 trial indicated that raltegravir 400 mg twice...
2.
Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults
Blanc F, Badje A, Bonnet M, Gabillard D, Messou E, Muzoora C, et al.
N Engl J Med . 2020 Jun; 382(25):2397-2410. PMID: 32558469
Background: In regions with high burdens of tuberculosis and human immunodeficiency virus (HIV), many HIV-infected adults begin antiretroviral therapy (ART) when they are already severely immunocompromised. Mortality after ART initiation...
3.
Standardization of an in vitro Model for Evaluating the Bioavailability of Topically Applied Compounds on Damaged Skin: Application to Sunscreen Analysis
Jacques-Jamin C, Jeanjean-Miquel C, Domergue A, Bessou-Touya S, Duplan H
Skin Pharmacol Physiol . 2017 Mar; 30(2):55-65. PMID: 28278501
Background: Information is lacking on the dermal penetration of topically applied formulations on in vitro skin models, under conditions where the stratum corneum (SC) is damaged. Therefore, we have developed...
4.
A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study
Witkowski B, Duru V, Khim N, Ross L, Saintpierre B, Beghain J, et al.
Lancet Infect Dis . 2016 Nov; 17(2):174-183. PMID: 27818097
Background: Western Cambodia is the epicentre of Plasmodium falciparum multidrug resistance and is facing high rates of dihydroartemisinin-piperaquine treatment failures. Genetic tools to detect the multidrug-resistant parasites are needed. Artemisinin...
5.
Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations
Duru V, Khim N, Leang R, Kim S, Domergue A, Kloeung N, et al.
BMC Med . 2015 Dec; 13:305. PMID: 26695060
Background: The declining efficacy of dihydroartemisinin-piperaquine against Plasmodium falciparum in Cambodia, along with increasing numbers of recrudescent cases, suggests resistance to both artemisinin and piperaquine. Available in vitro piperaquine susceptibility...
6.
Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment
Leang R, Taylor W, Mey Bouth D, Song L, Tarning J, Char M, et al.
Antimicrob Agents Chemother . 2015 May; 59(8):4719-26. PMID: 26014949
Western Cambodia is recognized as the epicenter of Plasmodium falciparum multidrug resistance. Recent reports of the efficacy of dihydroartemisinin (DHA)-piperaquine (PP), the latest of the artemisinin-based combination therapies (ACTs) recommended...